BETA
BETA
Axsome Therapeutics
AXSM60
$86.53arrow_drop_up0.63%$0.55
High Growth
AXSM60
$86.53
arrow_drop_up0.63%Performance History
| Key Stats | |
|---|---|
| Open | $86.33 |
| Prev. Close | $85.98 |
| EPS | -6.45 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 85.05 | 86.93 |
| 52 Week Range | 55.02 | 98.40 |
| Ratios | |
|---|---|
| EPS | -6.45 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
Correlated Companies
About Axsome Therapeutics (AXSM)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Herriot Tabuteau M.D.
- Headquarters
- New York
- Employees
- 393
- Exchange
- NASDAQ
Keep an eye on Axsome Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Axsome Therapeutics 's (AXSM) price per share?
The current price per share for Axsome Therapeutics (AXSM) is $86.53. The stock has seen a price change of $0.55 recently, indicating a 0.64% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Axsome Therapeutics (AXSM)?
For Axsome Therapeutics (AXSM), the 52-week high is $98.4, which is 13.72% from the current price. The 52-week low is $55.02, the current price is 57.27% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Axsome Therapeutics (AXSM) a growth stock?
Axsome Therapeutics (AXSM) has shown an average price growth of 0.41% over the past three years. It has received a score of 86 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Axsome Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Axsome Therapeutics (AXSM) stock price performance year to date (YTD)?
As of the latest data, Axsome Therapeutics (AXSM) has a year-to-date price change of 12.29%. Over the past month, the stock has experienced a price change of 9.52%. Over the last three months, the change has been 20.99%. Over the past six months, the figure is -4.48%. Looking at a longer horizon, the five-year price change stands at 232.17%.
help
Is Axsome Therapeutics (AXSM) a profitable company?
Axsome Therapeutics (AXSM) has a net income of -$239.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 87.84% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -91.58% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $270.6M, although specific revenue growth data is currently not available. The gross profit is $237.7M. Operating income is noted at -$182.91M. Furthermore, the EBITDA is -$244.54M.
help
What is the market capitalization of Axsome Therapeutics (AXSM)?
Axsome Therapeutics (AXSM) has a market capitalization of $4.11B. The average daily trading volume is 534.25K, indicating the stock's liquidity and investor engagement.
News
INVESTING
6/27/2024Should You Buy This Sinking Stock on the Dip?
6/24/2024
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
INVESTING
6/11/2024Why Axsome Therapeutics Stock Is Sinking Today
6/7/2024
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
6/5/2024
Axsome (AXSM) Down 6.1% Since Last Earnings Report: Can It Rebound?
ANALYST RATINGS
6/5/202415 Analysts Assess Axsome Therapeutics: What You Need To Know
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.